In this mono-center pilot trial, surgical patients who are at high risk to be admitted to intensive care will be screened and asked for participation. We are going to take blood and muscle samples at respecified time points to do metabolic, histological and molecular testing.
Aim of the study is to investigate (1) changes of the blood metabolome in patients with ICUAW (intensive care unit acquired weakness) and (2) identify metabolic components who are responsible for ICUAW or can be used as marker for ICUAW.
invasive mechanically ventilated critically ill patient with expected intensive care unit stay > 3 days
postoperative patient
≥ 18 years old
American Society of Anesthesiology (ASA) classification ≥ III
moribund patient
non-curative care (comfort care)
mechanically ventilated postoperative high-risk patients who are admitted to intensive care
Cohort
Prospective
Not listed
Metabolomics
Blood Metabolome will be isolated from blood samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) using mass spectrometry.
Muscle histology
Immunohistochemistry will be done in muscle samples. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Phosphoproteomics
Phosphoproteomics will be done in muscle samples using mass spectrometry. All samples will be screened for influence of Intensive Care Unit Acquired Weakness (ICUAW) and correlation with blood metabolome changes.
Identify possible predictors of muscle wasting in the blood metabolome preoperatively
Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) preoperatively associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.
Identify possible predictors of muscle wasting in the blood metabolome at ICU admission
Among the blood metabolome that will be measured, identify metabolites or combinations of metabolites whose high or low concentration(s) at ICU admission associate(s) with the amount of muscle loss. These metabolites are candidate biomarkers that could be used to identify individuals at risk of large muscle wasting and may give further insights into the mechanisms of muscle wasting.
Click on the lead sponsor to view all of their trials.
Technical University of Munich
Lead sponsor
Medical University of Vienna
Sponsor institution
Helmholtz Zentrum München
Collaborator
Charite University, Berlin, Germany
Collaborator
Medical University of Vienna
Collaborator
